Cyteir Therapeutics Inc

NASDAQ CYT

Data sourced from

and

Download Data

Cyteir Therapeutics Inc Depreciation and Amortization 3 year CAGR for the quarter ending September 30, 2023: 0.93%

Cyteir Therapeutics Inc Depreciation and Amortization 3 year CAGR is 0.93% for the quarter ending September 30, 2023. Depreciation and Amortization involve the systematic allocation of the cost of tangible and intangible assets over their useful lives. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Cyteir Therapeutics Inc Depreciation and Amortization for the quarter ending September 30, 2022 was USD 170.00 K, a 36.00% change year over year.
Cyteir Therapeutics Inc Depreciation and Amortization for the quarter ending September 30, 2021 was USD 125.00 K, a 16.82% change year over year.
Cyteir Therapeutics Inc Depreciation and Amortization for the quarter ending September 30, 2020 was USD 107.00 K.

NASDAQ: CYT

Cyteir Therapeutics Inc

CEO	Mr. Joseph S. Zakrzewski
IPO Date	June 18, 2021
Location	United States
Headquarters	128 Spring Street, Lexington, MA, United States, 02421
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Key trends